IntoCell P/CF

Mitä IntoCell tekee? IntoCell Inc is a biotechnology company based in Daejeon, South Korea, operating within the Health Care sector. The company has 43 full-time employees and is engaged in the research and development of advanced drug delivery technologies. IntoCell's primary focus is on the development of ADC (Antibody-Drug Conjugate) platform technology, with a specific emphasis on its ortho-hydroxy-protected aryl sulfate (OHPAS) platform. This OHPAS technology serves as a linker that connects therapeutic drugs to antibodies. Additionally, the company is developing payload modification technology (PMT), designed to minimize drug uptake into healthy cells, thereby improving targeted drug delivery. IntoCell also works on proprietary drug technologies relevant to ADC development. The company completed its initial public offering (IPO) on May 23, 2025, marking a significant milestone in its corporate development. Its headquarters are located in Daejeon, a city known for its strong presence in South Korea's biotechnology and research sectors. The company's website is http://intocell.co.kr/, where further information about its technologies and corporate activities can be found. As a relatively new entrant to the public market, IntoCell Inc is positioned to contribute to advancements in targeted cancer therapies through its innovative platform technologies. IntoCell on yksi Eurpooliin suosituimmista yhtiöistä.